Compare Ecolab Inc. (ECL) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Heron Therapeutics Inc — how do they compare? Ecolab Inc. trades at $274.17 (market cap $76.06B), while Heron Therapeutics Inc trades at $0.49 (market cap $84.50M). The key difference: Ecolab Inc. is far larger — about 900.1× Heron Therapeutics Inc's market cap, and Ecolab Inc. pays a 1.08% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ECL | HRTX | |
|---|---|---|
Market Cap | $76.06B | $84.50M |
Sector | Consumer Cyclical | Health |
52-Week High | $308.35 | $2.02 |
52-Week Low | $245.73 | $0.39 |
Enterprise Value | $84.81B | $182.40M |
Dividend Yield | 1.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $269.75, down 0.77% on the day, with a bearish technical signal. The stock shows strong fundamentals with 2025 revenue of $16.08B and net income of $2.08B, though recent quarterly EPS results have been mixed. The company recently completed the $4.75B CoolIT acquisition to strengthen its AI cooling portfolio, positioning high-tech as a growth engine. Analyst consensus remains strongly bullish with a $327.43 price target, representing 21% upside potential from current levels.
The outlook is positive given strong analyst support and strategic acquisitions, but risks include execution of the CoolIT integration, rising cost pressures, and mixed quarterly earnings performance. The stock's premium valuation (P/E 36.57) requires sustained earnings growth to justify current levels, making upcoming Q2 2026 results on July 28 critical for near-term direction.
HRTX trades at $0.44, up 2.63% today, with a bullish technical signal but bearish moving averages. The company reported Q1 2026 revenue of $151M with a net loss of $31M, maintaining a negative profit margin of -20.53%. Recent patent litigation developments and mixed earnings performance create uncertainty, though analyst consensus remains overwhelmingly positive with 94.7% buy ratings.
The outlook remains challenging with persistent losses and negative cash flow from operations, though improving net cash flow trends offer some optimism. Key risks include ongoing patent litigation and execution challenges in achieving profitability. The strong analyst support suggests potential upside if the company can deliver on its guidance and improve operational efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
